Abstract: Described is a process for producing a new immunosuppressant, a C-31 desmethyl, C-19/C-22 cyclic hemiketal biotransformation analog (Compound I) of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces, lavendulae ATCC No. 55209. Also disclosed is the C-31 methylated derivative (Compound II) of Compound I produced by enzymatic methylation using 31-O-desmethylimmunomycin O-methyl transferase, (DIMT), a methyl transferase enzyme. The macrolide immunosuppressants are useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
Type:
Grant
Filed:
August 1, 1991
Date of Patent:
December 28, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Shieh-Shung T. Chen, Raymond F. White, Georgette Dezeny, Byron H. Arison, Thomas R. Beattie, Amy M. Hale, Francis Dumont
Abstract: This invention claims a method for treating periodontal disease in mammals, including humans, by administering an effective amount of 4-amino-1-hydroxybutylidene-1,1-bisphosphonic acid or a pharmaceutically acceptable salt including the monosodium salt tridydrate (alendronate) of the formula: ##STR1## The compounds are useful in the treatment of alveolar bone loss associated with peridontitis and periodontal disease.
Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6970) ATCC No. 55281. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
Abstract: A child resistant drug assemblage is disclosed comprising a container having rows of spaced drug cell cavities each of which receives a unit drug dose of medication. The container is provided with a lock means that enables it to be readily opened by an adult but difficult to be opened by a child. Each of the drug dose modules has a plurality of drug cell cavities each of which can hold unit daily doses of a drug.
Abstract: Described is a process for producing a new immunosuppressant, a C-19/C-22 cyclic hemiketal (Compound I) biotransformation analog of FR-900520, under novel fermentation conditions utilizing the novel microorganism, Streptomyces sp. (Merck Culture Collection MA6968) ATCC No. 55279. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow, liver, lung, kidney and heart transplants.
Type:
Grant
Filed:
September 28, 1992
Date of Patent:
December 7, 1993
Assignee:
Merck & Co., Inc.
Inventors:
George M. Garrity, Magda M. Gagliardi, Shieh-Shung T. Chen
Abstract: Described is a new immunosuppressant, L-683,519, a monodemethylated rearranged derivative of L-679,934, (FK-506) produced under fermentation conditions utilizing the microorganism, unidentified Actinomycete (Merck Culture Collection MA 6474) ATCC No. 53828. The macrolide immunosuppressant is useful in preventing human host rejection of foreign organ transplants, e.g. bone marrow and heart transplants.
Type:
Grant
Filed:
April 22, 1992
Date of Patent:
December 7, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Byron H. Arison, Edward S. Inamine, Shieh-Shung T. Chen, Linda S. Wicker
Abstract: Described is a new enzyme, 31-O-desmethyl-FK-506 O-methyltransferase (FKMT) and its N-terminal amino acid sequence. This enzyme can specifically and preferentially methylate the C-31 hydroxy group in 31-O-desmethyl FK-506/FR-900506 and other 31-O-desmethyl analogs of FK-506/FR-900506 and related compounds such as 31-O-desmethyl immunomycin type molecules, also designated FK-520 and FR-900520 by Fujisawa. The enzyme can be isolated from a FK-506 producing microorganism Streptomyces sp. (Merck Culture Collection No. MA 6858) ATCC No. 55098. Employing the enzyme in its active form, supplemented with Mg.sup.+2 ion, in the presence of the methyl donor, S-adenosyl methionine (SAM), derivatives of 31-O-desmethyl FK-506, 31-O-desmethyl FK-520 and related 31-O-desmethyl compounds may be prepared.
Type:
Grant
Filed:
July 2, 1992
Date of Patent:
November 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Ali Shafiee, Patricia M. Cameron, David A. Boulton, Louis Kaplan, Haideh Motamedi
Abstract: Fibrinogen receptor antagonists of the formula: ##STR1## are disclosed for use in inhibiting the binding of fibrinogen to blood platelets and for inhibiting the aggregation of blood platelets.
Type:
Grant
Filed:
March 25, 1992
Date of Patent:
November 23, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Mark E. Duggan, Melissa S. Egbertson, Nathan Ihle, George D. Hartman, Laura M. Turchi, David Whitman
Abstract: This invention relates to compounds of structural formula ##STR1## which are inhibitors of squalene synthase and useful as cholesterol lowering agents.
Abstract: Amino O-aryl macrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by arylation and amination at C-3"/C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases and/or the prevention of rejection of foreign organ transplants. In addition, these macrolide immunosuppressants are useful in the topical treatment of inflammatory and hyperproliferative skin diseases and cutaneous manifestations of immunologically-mediated illnesses.
Type:
Grant
Filed:
May 6, 1992
Date of Patent:
November 16, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Peter J. Sinclair, Helen M. Organ, Matthew J. Wyvratt
Abstract: This invention relates to pharmaceutical compositions for use in the treatment of pain and inflammation and the treatment of muscle spasms and associated pain, soreness and tightness of muscles in mammalian organism, said composition comprising:(i) an analgesically and anti-inflammatory effective amount of (S)-ibuprofen, or a salt thereof, substantially free of (R)-ibuprofen; and(ii) an amount effective in the treatment of muscle spasms of at least one of the muscle relaxants, or a therapeutically active stereoisomer thereof, substantially free of its other stereoisomers.
Type:
Grant
Filed:
July 29, 1992
Date of Patent:
November 9, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Robert T. Sims, Thomas N. Gates, William Slivka
Abstract: This invention relates to a fungal microorganism MF5757 (ATCC 74167) isolated from bark discs of Quercus prinus L. (Chestnut Oak) and useful in a fermentation process to form a compound of formula (I): ##STR1## which is a squalene synthetase inhibitor and thus useful as a cholesterol lowering agent.
Type:
Grant
Filed:
July 20, 1992
Date of Patent:
November 9, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Wendy H. Clapp, Yu L. Kong, Jon D. Polishook
Abstract: O-Aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-42 and/or C-31. These compounds are useful in a mammalian host for the treatment of autoimmune diseases and diseases of inflammation, infectious diseases, the prevention of rejection of foreign organ transplants and the treatment of solid tumors.
Type:
Grant
Filed:
November 9, 1992
Date of Patent:
November 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Mark Goulet, William H. Parsons, Peter J. Sinclair, Frederick Wong, Matthew J. Wyvratt
Abstract: Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents. These compounds are also useful as inhibitors of squalene synthase, inhibitors of fungal growth, inhibitors of farnesyl-protein transferase and farnesylation of the oncogene protein Ras. These compounds are also useful in the treatment of cancer.
Type:
Grant
Filed:
September 10, 1992
Date of Patent:
November 2, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Gregory D. Berger, Robert W. Marquis, Jr., Albert J. Robichaud, Edward M. Scolnick
Abstract: Disclosed herein are compounds of structural formula (I) ##STR1## which are useful as cholesterol lowering agents and as inhibitors of squalene synthase.
Abstract: Compounds of formula (I), and salts and prodrugs thereof: ##STR1## wherein Q is the residue of an optionally substituted azabicyclic ring system;the dotted line represents an optional double bond;X represents H, --OH, .dbd.O or halo;R.sup.1 represents H, phenyl or thienyl, which phenyl or thienyl groups may be optionally substituted by halo or trifluoromethyl;R.sup.2 represents phenyl, thienyl or benzyl, any of which groups may be optionally substituted by halo or trifluoromethyl; andR.sup.3, R.sup.4 and R.sup.5 independently represent H, C.sub.1-6 alkyl, C.sub.2-6 alkenyl, C.sub.2-6 alkynyl, halo, cyano, nitro, trifluoromethyl, trimethylsilyl, --OR.sup.a, SR.sup.a, SOR.sup.a, SO.sub.2 R.sup.a, --NR.sup.a R.sup.b, --NR.sup.a COR.sup.b, --NR.sup.a CO.sub.2 R.sup.b, --CO.sub.2 R.sup.a or --CONR.sup.a R.sup.b ; andR.sup.a and R.sup.b independently represent H, C.sub.1-6 alkyl, phenyl or trifluoromethyl, are tachykinin receptor antagonists. They and compositions thereof are useful in therapy.
Type:
Grant
Filed:
June 29, 1992
Date of Patent:
October 26, 1993
Assignee:
Merck Sharp & Dohme, Limited
Inventors:
Tamara Ladduwahetty, Christopher J. Swain
Abstract: Two acyclic tricarboxylic acid compounds have been isolated from the fermentation of Sporormiella intermedia. The compounds and their derivatives may be used as antifungal agents, cholesterol lowering agents and as anticancer agents.
Type:
Grant
Filed:
October 19, 1992
Date of Patent:
October 19, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Claude Dufresne, E. Tracy T. Jones, Leslie A. Ferrell
Abstract: An anionic/cationic polymer mixture comprising:(a) a polyanion selected from polyacrylic acid, polymethacrylic acid, and polymaleic anhydride, each optionally copolymerized with each other, or optionally copolymerized with acrylamide up to a molar unit ratio of 1:1, provided that the total polyanionic weight average molecular weight is from about 1 to 5 thousand, and(b) the polycation poly(dimethyldiallylammonium chloride) having a weight average molecular weight of from about 25 thousand to 1 million,wherein the weight ratio of polyanion (a) to polycation (b) is from 1:2 to 1:8, has been found to give excellent inhibition of the formation, deposition and adherence of various alkali metal and alkaline earth metal scales, e.g., sodium sulfate, sodium carbonate, and calcium carbonate scales in the stringent conditions which characterize black liquor heaters, evaporators, etc.
Abstract: A method for flow injection analysis of total inorganic phosphate contained in an aqueous system such a cooling tower or boiler is described which uses a reducing agent and preservative composition therefore as the carrier for the sample to be analyzed, thereby creating a facile process which permits conversion of the various polyphosphates to orthophosphate and development of the molybdenum blue complex color reaction at 60.degree.-95.degree. C. and under 2-10 psi. This method has less stringent pressure and temperature requirements than those employed heretofore, thus permitting the use of more reliable and economic devices for measuring total inorganic phosphate in the field.
Abstract: O-Heteroaryl, O-alkylheteroaryl, O-alkenylheteroaryl and O-alkynylheteroarylmacrolides of the general structural Formula I: ##STR1## have been prepared from suitable precursors by alkylation and/or arylation at C-3" and/or C-4" of the cyclohexyl ring. These macrolide immunosuppressants are useful in a mammalian host for the treatment of autoimmune diseases, infectious diseases, the prevention of rejection of foreign organ transplants and/or related afflictions, diseases and illnesses.
Type:
Grant
Filed:
August 5, 1992
Date of Patent:
October 12, 1993
Assignee:
Merck & Co., Inc.
Inventors:
Peter J. Sinclair, Joung Goulet, Frederick Wong, Mark Goulet, William H. Parsons, Matthew J. Wyvratt